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Targeted knock-in mice expressing the oxidase-
fixed form of xanthine oxidoreductase favor tumor
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Xanthine oxidoreductase has been implicated in cancer. Nonetheless, the role played by its
two convertible forms, xanthine dehydrogenase (XDH) and oxidase (XO) during tumor-
igenesis is not understood. Here we produce XDH-stable and XO-locked knock-in (ki) mice to
address this question. After tumor transfer, XO ki mice show strongly increased tumor
growth compared to wild type (WT) and XDH ki mice. Hematopoietic XO expression is
responsible for this effect. After macrophage depletion, tumor growth is reduced. Adoptive
transfer of XO-ki macrophages in WT mice increases tumor growth. In vitro, XO ki macro-
phages produce higher levels of reactive oxygen species (ROS) responsible for the increased
Tregs observed in the tumors. Blocking ROS in vivo slows down tumor growth. Collectively,
these results indicate that the balance of XO/XDH plays an important role in immune
surveillance of tumor development. Strategies that inhibit the XO form specifically may be
valuable in controlling cancer growth.
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XOR is an enzyme that is expressed in various organsincluding liver, kidney, intestine, mammary glands, andcapillary endotherial cells. The enzyme is a homodimeric
protein with a relative molecular mass of 290,000 and is com-
posed of independent subunits; each subunit containing one
molybdopterin (Moco center), two nonidentical [2Fe-2S] type
iron sulfur clusters (Fe/S centers) and one FAD as cofactors1,2.
The enzyme catalyzes the hydroxylation of hypoxanthine to
xanthine, and xanthine to uric acid at the Moco center, and two
electrons are transferred to the Mo atom (MoVI to MoIV) of
Moco in each reaction, thus introduced that the electrons are
further transferred rapidly to FAD via two Fe/S centers, and
reduction of NAD+ or oxygen occurs2–4. Mammalian XOR can
be found in two inter-convertible forms: xanthine dehydrogenase
(XDH, EC 1.1.1.204), which is the genetically coded form, which
uses NAD+ as a cofactor, and xanthine oxidase (XO, EC 1.1.3.22),
which uses oxygen. Whereas XDH activity leads to NADH pro-
duction, XO activity generates ROS, such as superoxide anions
(O2−) and hydrogen peroxide, which are involved in diverse
physiological roles, e.g., in host defense against infectious
pathogens, or in the pathology of postischemic reperfusion
injury5–7. In addition, results from XOR-deficient mice demon-
strated an important physiological role of the XO form in lacta-
tion8. Since then, additional physiological and pathological roles
of XOR-derived ROS have been found2,9.
The conversion between XDH and XO can occur either irre-
versibly by limited proteolysis, or reversibly by oxidation of XDH
thiol groups10–12, and structural differences and mechanisms of
conversion between the two forms were assessed by mutagenesis
studies and crystal structural studies10–17. It has been shown that
the conversion of the XDH form to the XO form leads to cyto-
toxicity and death of the damaged cells18. Accordingly, XOR
inhibitors, such as febuxostat and allopurinol, have shown a
protective effect in diseases such as atherosclerosis and chronic
heart failure19.
XOR has also been implicated both in the pathogenesis20 and the
prevention21 of cancer through the action of XOR-derived ROS22.
A decrease of XOR activity has been found in tumor cells leading to
a shift in the purine anabolic-catabolic balance, which should
confer selective advantages to malignant cells.23. XOR down-
modulation has been linked to more aggressive breast cancer24 and
pharmacologic inhibition of XOR increased tumor burden in a
mouse xenograft model25. Furthermore, XO and also XDH under
hypoxic conditions are a source of ROS and subsequent DNA
damage, which can cause malignant tumors, reported in several
studies26,27. Although the involvement of XOR in cancer has been
proposed, the mechanisms that link the XDH and XO forms to
tumor-related inflammatory pathways are not clear.
The physiological and pathological roles of the XDH/XO
conversion remain controversial. One key reason is the conver-
sion of XDH to XO by lysosomal protease or oxidation of sulf-
hydryl groups during sample preparation, making the evaluation
of when, where, and how much of XOR exists in the XO form
very difficult to assess. Here, we constructed XOR gene-modified
mice to examine the function of the two XOR forms. Based on
previous mutagenesis studies and X-ray structural determination
of rat enzyme28,29, we constructed stable XDH type mutant
(C995R) and XO-locked type mutant (W338A/F339L) knock-in
mice. To address the specific contribution of XDH and XO in
cancer, we have investigated tumor growth after syngenic tumoral
cells transfer in XDH ki and XO ki mice. In XO ki mice tumor
growth was strikingly enhanced, which was dependent on XO ki
macrophages and could be prevented by blocking the excessive
ROS produced by XO ki macrophages. As a result, increased
numbers of tumor infiltrating Tregs were found responsible for
enhanced tumor growth.
Results
Generation of XOR mutant knock-in mice. Two types of XOR
mutant knock-in (ki) mice, XDH ki and XO ki, were generated by
replacing wild type XOR in C57BL/6 mice (Fig. 1a). W338A/
F339L mutations were introduced into exon 11 of the Xdh gene in
the case of XO ki (Fig. 1b). In the case of the XDH ki, C995R
mutation was introduced into exon 27 of the Xdh gene (Fig. 1c).
The WT Xdh locus, construct of targeting vector, and the targeted
allele after homologous recombination are depicted in Supple-
mentary Fig. 1A (for XO ki) and S1B (for XDH ki) and further
detailed characterization of these knock-in mice is shown
in Supplementary data and Figs. 2–5. Homozygous XOR mutant
mice were viable, present at the expected Mendelian ratios and
did not exhibit overt abnormalities.
Growth and survival of XOR mutant mice. Growth of XO ki
and XDH ki was evaluated by body weight gain for up to
19 weeks (Supplementary Fig. 6). There was no difference
between the growth of XOR mutant mice and that of WT mice.
The estimation of survival distribution for XO ki and XDH ki
mice was compared with WT mice by the Kaplan-Meier method
(Supplementary Fig. 7). There was no noticeable difference in
survival between XOR mutant mice and WT mice.
Expression of modified XOR protein and activity in ki mice.
Expression of mutated XOR in XO ki and XDH ki mice was
examined by Western blot analysis of tissue lysate proteins from
lung and liver, using anti-rat XOR antibody, which cross-reacts
with purified mutated XOR proteins. An intense 150 kD band
could be detected in XO ki and XDH ki lung and liver homo-
genates similar in size and intensity to that in WT counterparts
(Supplementary Fig. 8A, B). To assess if targeted XOR mutations
could affect XOR activity, we next quantified total XOR activity
and XO activity in liver homogenates by assessing xanthine
conversion to urate in presence or absence of NAD respectively.
In WT liver tissues and XDH stable (C995R) mutant mice, the
vast majority of XOR activity was accounted for by XDH activity
as XO activity represented <20% of the total XOR activity
(Table 1). By contrast in the XO-locked (W338A/F339L) liver
homogenates, XO activity was dominantly expressed and no
XDH activity could be detected (Table 1). The liver XO activity
was not due to proteolytic cleavage since as mentioned above a
single 150 kD band was detected in XO ki liver homogenates.
Purification and characterization of XOR from ki mice. XOR of
XO ki and XDH ki was purified from the corresponding mouse
liver lysates. A single band on SDS-PAGE could be obtained in
XO ki (Fig. 2a) and XDH ki (Fig. 2b). We further assessed that the
purified XOR (C995R) from XDH ki was resistant to the con-
version into the XO form since it lacks the Cys995 involved in the
disulfide bridge formation. Indeed, XOR from XDH ki was unable
to be converted into XO by chemical modification of the intra-
molecular sulfhydryl group with 4, 4′-dithiodipyridine (Fig. 2c).
In the same conditions, XDH from bovine milk was converted to
XO (Fig. 2d).
Next, we characterized the XO-locked (W338A/F339L) mutant
enzyme from XO ki. The purified mutated enzyme generated
higher O2– levels compared to WT enzyme (Fig. 2e). Altogether,
our results indicated that XDH ki expressed an XDH-stable
(C995R) mutant protein unable to be converted into XO and that
XO ki expressed a XO-locked mutant protein overproducing
superoxide.
XO ki mice exhibit increased tumor growth. XOR has been
shown to play a role in tumor growh20,22,23,30–32. As the
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respective roles of XDH and XO and the cells expressing them are
not clear in susceptibility to tumor growth, we tested our mice
expressing the XO and XDH forms in an in vivo model of sub-
cutaneously transferred CMT93 colon carcinoma cells (expres-
sing WT XOR). In this experimental tumor model, tumors are
initially controlled by the adaptive immune response. As shown
in Fig. 3a, CMT93 tumor volume reached rapidly a larger size in
XO ki mice compared to XDH ki or control WT mice. These
clinical observations were confirmed by histological analysis of
the dissected tumors, where tumors were consistently bigger in
XO ki mice compared to XDH ki and WT mice (Fig. 3a).
However, tumor infiltrating T cells and macrophages (shown by
anti-CD3 and anti-MAC-2 immunohistology, respectively) and
tumor neovascularization (shown by anti-CD31 immunohistol-
ogy) were not significantly different between mouse genotypes
(Supplementary Fig. 9). In addition, we explored the pro-tumor
potential effect of the XO form using two other adoptively
transferred tumor models, the MC38 colon carcinoma cells and
the B16 F0 melanoma cells. The results in Fig. 3b showed that
also MC38 tumor grew more aggressively in XO ki mice than in
XDH ki mice: 402.1+/− 29.05 in XO ki vs 229.6+/− 28.09 in
XDH ki mice. Moreover, the average volume of B16 melanoma
recovered from the XO ki mice was 60% larger than that from
XDH mice: 489.9+/− 48.37 in XO ki vs 308.2+/− 40.7 XDH
ki mice.
Uric acid may contribute to cancer pathogenisis33. To test the
role of uric acid in tumor progression, we measured serum uric
acid levels in mice after the CMT93 tumor transfer. As shown in
Fig. 3c, we found no significant difference between serum uric
acid levels in XO ki, XDH ki, and WT mice, thus suggesting that
uric acid does not account for increased tumor growth in XO
ki mice.
XO ki macrophages are responsible for faster tumor growth.
To investigate if bone-marrow-derived cells or radio-resistant
non-hematoipoietic cells are responsible for the increased tumor
growth in XO ki mice, we generated chimeric mice by trans-
plantation of bone marrow (BM) from WT, XO ki and XDH ki
mice into lethally irradiated WT mice (950 Rad). Chimeric mice
were then challenged with tumor cells 8 weeks after the bone
marrow transfer (when the adaptive immune system was rees-
tablished). As shown in Fig. 4a, only transfer of XO ki BM to WT
mice led to increased tumor growth in these mice thus demon-
strating that bone-marrow-derived cells are responsible for the
tumor-promoting effect. Amongst hematopoietic cells, we speci-
fically addressed the role of macrophages in increased tumor
growth in XO ki, investigating the effects of macrophage deple-
tion on tumor progression. Macrophage depletion was achieved
by treating mice with liposomal clodronate, which induced >80%
depletion of macrophages by FACS analysis of peritoneal and
spleen cells (data not shown). As shown in Fig. 4b, liposomal
clodronate treatment inhibited tumor growth in the XO ki mouse
group. Next, we sought to examine the pro-tumoral potential of
XO ki macrophages. Prior studies have shown that adoptively
transferred immune suppressive macrophages stimulate tumor
growth34. Accordingly, in vitro differentiated XO ki and XDH ki

































Fig. 1 Design and construction of mouse XO ki and XDH ki mutants. a Mutant structures are designed from rat XOR W335A and F336L double mutant
(PDB ID: 2E3T), and rat XOR C535A, C992R, and C1324S triple mutant (PDB ID: 1WYG). Amino acid cluster consisted of R334, W335, R426, and F549 are
shown in space fill model. Upper inset, Active site loop (Gln422-Lys432) is shown in light blue. Corresponding residues to those mutated in XO ki mice are
shown in red. Lower inset, Crystal structure around Cys535 in the loop connecting FAD and Molybdenum domains (green color). Cys992 in the
molybdenum domain corresponding to the mutated residue in XDH ki mice is shown in cyan. b Targeted mutation sites of the murine Xdh gene for XO ki.
The W338A/F339L mutation was introduced into exon 11. Minor differences in numbering of amino acids in mice used in this study are due to minor
changes of amino acid sequences between rat and mouse. Therefore, W338 and F339 residues of murine XOR correspond to W335 and F336 residues of
rat enzyme, respectively. c Targeted mutation sites of the murine Xdh gene for XDH ki. The C995R mutation introduced into exon 27. C995 residue of
murine XOR corresponds to C992 residue of the rat enzyme
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into WT mice that had been given CMT93 tumor cells 48 h
previously. Remarkably, XO ki BMDM potently stimulated tumor
growth compared with XDH ki macrophages in WT mice
(Fig. 4c). Taken together; these results indicate the potent ability
of XO macrophages in controlling increased tumor growth.
Characteristics of tumor-associated macrophages in ki mice. As
XO ki macrophages were able to favor tumor growth, we hypo-
thesized that they might be phenotypically different compared to
XDH ki macrophages. Indeed, tumor-associated macrophages
(TAM) can have pro-tumor or anti-tumor activities. Often M1-
like (anti-tumor) and M2-like (pro-tumor) differentiation were
used to classify them, TAM in malignant tumors resemble M2-
type macrophages. However, this classification is oversimplified
since in certain tumors infiltrating macrophages have a mixed
phenotype on a scale in which M1 and M2 represent the
extremes35–37.
We first proceeded to quantify by qPCR M1 and M2 markers
in tumors of XO or XDH ki mice after calibration to CD11b or
F4/80 expression. We observed strikingly increased expression of
Fpr2 in XO mice, a marker for M1 macrophages and/or
inflammation, whereas XDH ki mice expressed higher levels of
arginase (arg), a marker for M2 macrophages (Fig. 4d) within the
tumor. However, expression of other M1/M2 markers (such as
CCL2, IL-10, and EGR2) was similar between XO ki and XDH ki
tumor infiltrating macrophages (Fig. 4d).
Analysis of gene expression in XO ki and XDH ki BMDM. As
tumor infiltrating macrophages are heterogenous, we compared
the results with in vitro differentiated and activated macrophages.
We therefore analyzed M1 and M2 marker expression by RT-
qPCR, FACS, and ELISA in activated BMDM from XO and XDH






















































































Fig. 2 Verification of the expression in the XOR mutant ki mice. Details of mouse liver XOR purification were described in the “Methods” section. a SDS-
PAGE analysis of each step of XOR purification from XO ki mouse liver; b SDS-PAGE analysis of each step of XOR purification from XDH ki mouse liver.
Analysis was performed in a 5–20% polyacrylamide gel. Lane 1, liver cytosol fraction; lane 2, ammonium sulfate fractionation (20–55%); lane 3, anion
exchange column (DE 52) fraction; lane 4, calcium phosphate column (Macro-Prep ceramic hydroxyapatite) fraction; lane 5, folate-affinity column side-
fraction. Lane 6, folate-affinity column fraction. Lanes 1, 2, and 3 contain 2 µg of protein. Lanes 4, 5, and 6 contain 200 ng of protein. Protein bands in the
electrophoresis gel were stained with Oriole. The arrowhead on the right side indicates the protein band derived from XOR. The molecular masses of the
size standards are marked on the left side in kilodaltons. Purified XORs from the mutant mice were characterized to verify the proper expression of mutant
XOR enzymes. To identify the XDH-stable property, purified XOR from XDH ki mice was analyzed. c Conversion of bovine milk native-XDH to XO by
chemical modification. d Conversion from XDH to XO of XDH ki XOR by chemical modification. 4,4′-Dithiodipyridine was reacted with XDH form enzyme
in 50mM sodium phosphate buffer, pH 7.4 at 25 °C. Reactants were withdrawn after incubation at indicated intervals, and O2-dependent urate formation,
NAD+-dependent urate formation, and NAD+-dependent NADH formation activities were assayed. Detail of assays was as described in the “Methods”
section. e Comparision of O2− production ratio during XOR turnover. The XO form of the purified mouse XOR enzyme was used in the assay. The activity
of cytochrome c reduction was a difference between the presence and absence of superoxide dismutase, and the value indicated O2− formation activity.
O2− flux is the percentage at which electrons generated by oxidation of xanthine flowed into O2−
Table 1 Comparision of liver lysate XOR activity





NAD (−) NAD (+) NAD (−) NAD (+)
Wild-type litter mate 0.64 ± 0.05 3.97 ± 0.11 0.53 ± 0.06 4.10 ± 0.31
Mutant 1.22 ± 0.14 1.19 ± 0.15 0.66 ± 0.14 4.11 ± 0.41
NAD (−), rate of urate formation for xanthine-O2 turnover
NAD (+), rate of urate formation for xanthine-NAD+ and xanthine-O2
Sample number of XO ki mice, wild type litter mate of XO ki, XDH ki mice, and wild type litter
mate of XDH ki were 7, 5, 6, and 6, respectively. Activities indicated by mean ± SEM values
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ki activated macrophages. First, as found by qPCR, Fpr2 was up-
modulated in XO ki activated macrophages whereas arg was
down-modulated (Fig. 5a), recapitulating the regulation pre-
viously found in tumor infiltrating macrophages (Fig. 4d). In
addition, XO ki BMDM expressed more IL-1β and CCL2. By
FACS analysis, we found decreased expression of the M2 marker
arg in XO ki cells, corroborating the results obtained at the RNA
levels, whereas another M2 marker, EGR2 was similarly expressed
in both XO ki and XDH ki macrophages. CD206, a mannose
receptor and C-type lectin, primary expressed on the surface of
c
b




























































WT XDH ki XO ki














Fig. 3 XO ki mice exhibited abnormal tumor growth. a CMT93 tumor cells were transferred subcutaneously in the flank of WT, XO ki, and XDH ki mice.
Results are expressed as the mean ± SEM of tumor volume from 12 mice. Tumors were resected 15 days after inoculation and subjected to hematoxylin and
eosin staining. Representative examples of H&E sections of tumors from WT, XDH ki, and XO ki mice. Images are taken at X40 (top panel, scale bar
represents 1 mm) or X400 (bottom panel) magnification. bMC38 and B16 F0 melanoma tumor volume in XDH ki and XO ki mice. Data shows the mean ±
SEM of tumor volumes from 6 to 8 mice per group. c Seric uric acid levels of CMT93 tumor-bearing WT, XDH ki, and XO ki mice at day 15 after tumor
transfer. Data show representative mean ± SEM of 11 mice. P values were determined by unpaired Student’s t test. Difference were considered statistically
significant at *p < 0.05, **p < 0.01. Source data are provided in Source Data excel file
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M2 macrophages was more abundantly expressed on XO ki
BMDM. Finally, XO ki macrophages expressed more IL-6, as
demonstrated by FACS (Fig. 5b).
Cytokine levels were also measured by ELISA in supernatants
of LPS-stimulated BMDM. We found that XO ki macrophages
secreted higher levels of IL-10 and TNF-a than XDH ki
macrophages (Fig. 5c).
Increased ROS production upon XO ki macrophage activation.
We assessed by flow cytometry whether the mutant mice had
different resident peritoneal cell populations. We found a
significant increase in the total peritoneal cell numbers in XO ki
mice compared to XDH ki and WT mice (Fig. 6a). To identify
specific cell populations in the peritoneal cavity of mice, cells were
stained for the macrophage marker F4/80 and neutrophil marker
Gr-1. Flow cytometry analysis identified a statistically significant
increase in F4/80+ macrophage number when comparing the XO
ki mice to XDH ki or WT mice (Fig. 6a), whereas the numbers of
Gr-1 expressing neutrophils were similar (results not shown). No
significant difference appeared between the three groups of mice
in the number of macrophage in the spleen and bone marrow
(results not shown).




































































































































XO ki + clodronate
Fig. 4 XO ki macrophages are involved in tumor progression. a Tumor growth of subcutaneous CMT93 tumors in WT→WT, XDH ki→WT, and XO ki→
WT bone marrow chimeric mice (n= 10 mice per group). Tumor growth was increased in XO ki→WT mice compared with WT→WT and XDH ki→WT
mice. b WT, XDH ki, and XO ki mice were injected intraperitoneally with clodronate-loaded liposome suspension prior to tumor injection. CMT93 tumor
cells were injected into the flank of mice. Tumor growth was measured using a caliper. Results are expressed as the mean ± SEM of tumor volumes (n=
8–11 mice per group). c CMT93 tumor growth in WT mice adoptively transferred with XO ki or XDH ki BMDMs. Data shows the mean ± SEM of tumor
volumes (4–5 mice per group). d Expression levels of M1 and M2 markers in tumors were measured by qRT-PCR and expressed as fold increase over
CD11b expression. Results are expressed as the mean ± SEM of RNA extracted from at least 4 mice per group. Difference were considered statistically
significant at *p < 0.05, **p < 0.01, *** p < 0.001. Source data are provided in Source Data excel file
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Fig. 5 Characterization of XO ki and XDH ki BMDM. a XDH ki and XO ki BMDM were primed overnight with or without 100 ng/mL of Pam3CSK4. RT-
qPCR analysis of M1/M2 markers expressed as ratio of primed over unprimed cells. Significant increase of gene expression between XO ki and XDH ki
macrophages is indicated. b Expression of arg, CD206, EGR2, and IL-6 on Pam3CSK4 primed BMDM was analyzed by FACS. c XDH ki and XO ki BMDM
were primed overnight with or without LPS (100 ng/ml). The supernatants were analyzed for IL-10, TNF, and IL-6 by ELISA. a–c Results are expressed as
the mean ± SEM from differentiated BMDM from at least 3 mice per group. P values were determined by t-tests. *p < 0.05, **p < 0.01, ***p < 0.001. Source
data are provided in Source Data excel file
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To investigate functional differences in peritoneal macrophages
from the different XOR mutant mice, we examined ROS
generation upon stimulation of peritoneal macrophage cells.
Detection of DCF dye by flow cytometry was used as an indicator
of ROS production. As shown in Fig. 5b, LPS or PMA treatment
for 3 h led to a significant increase of ROS production in XO ki
macrophages when compared with that of LPS or PMA-treated
XDH ki or WT macrophages confirming the role of XO as a
major source of ROS in these cells.
Increased Tregs in XO ki tumors. FoxP3+ regulatory T cells
(Tregs) have a prognostic relevance in cancer, high Treg/CD4 T
cell ratios correlate with more aggressive cancers38. Interestingly
Treg differentiation has been shown to be modulated by ROS39.
Taking into account the different ROS levels measured in XO ki
and XDH ki macrophages, we hypothesized that Treg ratios in
intratumoral T cells could vary between XO ki and XDH ki mice.
Indeed, flow cytometric analysis of tumor-infiltrating lympho-
cytes from XO ki mice revealed higher frequencies of Foxp3
regulatory T cell (Fig. 7a). By contrast, no differences could be
observed with CD11b+ myeloid cells or F4/80+ cells (Fig. 7b).
Next, we examined the direct effect of macrophages on Foxp3
expression by CD4+ T cells. Differentiated XO ki and XDH ki
BMDM were incubated with OTII CD4+CD25− T cells at a 1-to-
5 ratio in the presence of OTII peptide and TGFbeta and the
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Fig. 6 Increased ROS production by peritoneal XO ki macrophages. Peritoneal cells were harvested from WT, XDH ki, and XO ki mice, immunostained and
flow cytometry performed to identify F4/80+ macrophages. a Total number of PEC from WT and XDH ki and XO ki mice, and F4/80+ macrophages.
Results are expressed as the mean ± SEM of percentage of total cells or absolute numbers (n= 13–20 mice per group). b PEC cells were stimulated ex vivo
with LPS or PMA for 3 h. ROS production in F4/80+ macrophages was measured by flow cytometry using CM-DCFH dye. Results are expressed as the
mean ± SEM (n= 5-6 mice per group). Difference were considered statistically significant at *p < 0.05, **p < 0.01. Source data are provided in Source Data
excel file
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frequency of Foxp3+ Treg cells was examined at day 5 (Fig. 7c).
The percentage of FoxP3+ cells amongst the CD4+CD25+ cells
was significantly increased upon coculture of T cells with XO ki
BMDM, confirming their Treg-inducing capacity. To study if
ROS coud be involved in the induction of Treg by XO ki
macrophages, we tested the effect of N-Acetyl Cysteine (NAC), a
ROS scavenger. XO ki BMDM cultured in the presence of NAC
significantly reduced the percentage of Tregs (Fig. 7c), demon-
strating the ROS dependency of Treg induction. Based on this
observation, we tested the anti-tumoral activity of NAC in vivo.
NAC was given into drinking water 24 h after injection of CMT93
tumor cells in XO ki mice. We found that tumor growth was
significantly inhibited in the NAC treatment group compared to
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Fig. 7 Increased Tregs in XO ki tumors. Tumors were resected 12 days after inoculation and enzymatically digested. a, b Graphs and FACS profiles
indicating the proportions of CD4+Foxp3+ cells, Gr-1+ neutrophils and F4/80+ macrophages in tumors from WT, XDH ki, and XO ki mice. Results are
expressed as mean ± SEM from 5 mice. c Representative FACS profiles and quantification of CD4+CD25+Foxp3+ T cells in vitro. XDH ki and XO ki
BMDMs were cultured with CD4+CD25- T cells and stimulated with OT-II peptide for 5 days in the presence or absence of 1 mM NAC. Results are
expressed as mean ± SEM. d Tumor weights 9 days after implantation of CMT93 cells in XO ki mice treated with vehicle or NAC at 20mM in drinking
water. Data show the mean ± SEM of tumor weight from 5 mice per group. P values were determined by t-test. Difference were considered statistically
significant at *p < 0.05, **p < 0.01. Source data are provided in Source Data excel file
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Discussion
XDH is ubiquitously present in most organisms, from bacteria to
human. However, only the mammalian XDH can be converted
into the XO conformation, but the pathophysiological reasons
underlining the conversion into the XO form remains elusive.
The generation and analysis of the Xdh gene-modified mice,
expressing knocked-in XDH stable (C995R) mutant protein, is an
effective method to elucidate the physiological function of
dehydrogenase/oxidase conversion. On the other hand, XO is an
endogenous source of reactive oxygen species such as hydrogen
peroxide and super oxide in vivo. The other Xdh gene-modified
mice, express knocked-in XO-locked (W338A/F339L) mutant
protein. In addition to the physiological role for the purine
metabolism, XO-locked mutants can constantly overproduce
superoxide in XO ki mouse cells.
These latter mice constitute an unvaluable tool to evaluate the
effect of superoxide in vivo.
It is well known that insufficient XOR activity causes serious
consequences due to accumulation of high concentration of
hypoxanthine and xanthine in blood of most of mammalian
animals except primates8,40. However, both XDH ki and XO ki
mice have a normal phenotype and growth, and in particular no
sign of renal failure and premature death, which suggests that
XOR mutant enzymes expressed normally and sufficiently with
normal physiological function in the XOR gene-modified mice.
Indeed, we found that the mutant XOR enzymes were similarly
expressed in the lungs and liver of XDH ki, XO ki, and wild-
type mice.
Our results questioned a previous publication in which the
death of XOR knock-out mice pups was attributed to insufficient
milk secretion8. It was suggested that the structural changes into
the XO form affected lipid secretion in milk. Therefore, deficient
breast-feeding ability in XDH ki mice was expected. However,
since the growth of XDH ki mice was similar to that of XO ki and
WT mice, it seems that even with reduced amounts of XO in milk
(such as the situation in lactating XDH ki mice), breast-feeding is
not impaired. Phenotypic changes such as early aging and
tumorigenesis were expected in XO ki mice, since XO-locked
(W338A/F339L) mutant constantly produces superoxide in their
cells. Contrary to expectation, these mice did not have any
spontaneous phenotype. Growth and life span of XO ki mice were
also normal.
Purified XOR enzymes from the XOR gene-modified mice were
characterized to confirm that the mutant XOR enzymes have
been correctly expressed in vivo. Rat C995R mutant resisted to
complete conversion to XO when the enzyme was treated with
sulfhydryl-modifying reagent, 4, 4′-dithiodipyridine41. Purified
XOR from the XDH ki mice resisted to conversion to XO form
similar to the property of rat C995R mutant enzyme (Fig. 2). On
the other hand, rat W335A/F336L mutant has the XO-locked and
superoxide hyper-generation properties42. Purified XOR from the
XO ki mice constantly exhibited oxidase activity and pre-
dominantly generated superoxide similar to the property of rat
W335A/F336L mutant enzyme. Altogether, these results con-
firmed that XDH-stable or XO-locked mutants were successfully
introduced into XDH ki or XO ki, respectively.
Several studies have reported a role of the XOR enzyme in
cancer. However, surprisingly little is known about the molecular
mechanisms underlying the involvement of the two forms of this
enzyme in immune pathways and tumorigenesis. Moreover, how
and in which cell types an imbalance in oxidase and deydrogenase
forms could influence tumor growth is not known. The previous
studies concerned XOR expression mostly in cancer cells and
both, positive or negative influences of XOR on tumor growth,
have been reported30,43,44. We therefore here examined the
function of our XO and XDH knock-in mice in the syngenic
subcutaneously transplanted colorectal cancer model CMT93. In
our model, the transplanted tumor cells expressed wild-type XOR
activity. The most relevant finding of this study was that mice
expressing the XO-fixed form showed strongly enhanced tumor
growth when compard to XDH-locked or WT mice.
Cancer infiltrating and systemic myeloid-derived suppressor
cells have been associated with enhanced tumor growth. These
tumor-derived suppressor cells are a heterogenous mixture of
neutrophils, macrophage/monocyte and dendritic cells with
varying phenotypes45. As in our mice neutrophil marker
expressing cells were similar in XO and XDH ki mice, we con-
centrated on tumor-associated macrophages (TAMs). TAMs have
a key role in cancer-related inflammation and immune response/
immune escape. TAMs are a heterogenous cell population that
can be conventionnally divided into two major subgroups (M1
and M2). While M2−type macrophages are thought to promote
tumor progression, M1-type macrophages are well-adapted to
promote a strong immune response and eliminate tumor cells46.
However, it is important to mention that TAMs can adopt
multiple intermediate phenotypes with different features47 and
that tumors in vivo can express both M1 and M2 markers48,49.
We established that XO ki macrophage favored tumor progres-
sion, based on XO ki bone-marrow transfer experiments or XO ki
BMDM injection into wild-type mice, which both promoted
tumor growth. Further demonstration was provided by liposomal
clodronate treatment which, by depleting macrophages, inhibited
tumor growth in the XO ki mouse. We hypothesized that mac-
rophages from XO ki mice were phenotypically different and
prone to M2 differentation and pro-tumor activity. We found
increased CD206 expression, increased proinflammatory cytokine
secretion of IL1β, IL-6, and TNFα, as a consequence of inflam-
mation, increased Fpr2 expression, but also increased secretion of
the anti-inflammatory cytokine IL-10 in XO ki macrophages
upon activation. There are three possible interpretations for this.
First, the regulation of the measured markers and cytokines in
XO ki macrophages could be the reflection of macrophage dif-
ferentiation into mixed M1 and M2 populations. Indeed M1 and
M2 macrophages were reported to co-exist inside tumors48,49.
Secondly, the phenotype of activated XO ki macrophages could
reflect XO ki macrophage differentiation towards M2b, a subset
of M2 macrophages, which are pro-tumorigenic and express
concomitantly CD206, proinflammatory IL1β, IL-6, TNFα, and
anti-inflammatory IL-10 cytokines50. Finally, the phenotype coud
reflect the specific macrophage environment which may alter the
gene expression of the different subtypes. It is difficult to dis-
criminate between these possibilities, due to multiple inter-
mediate phenotypes and plasticity observed between M1 and M2
marker expressions47.
We speculated that higher ROS production in XO ki mac-
rophages could lead to increased Treg differentiation. Tumors
with high Treg/T cell ratios were favorable for tumor growth
and predicted poor cancer patient survival51–53. Strikingly, ROS
have dose-dependent effects on T cells. At low concentrations,
ROS are required for effector T cell differentiation, at higher
levels, they down-regulate T cell activity and switch the
immune response towards Treg phenotype and, at very high
concentrations, they become cytotoxic54,55. Indeed, we found
an increase in Tregs in the fastly growing tumors in XO ki mice
compared to XDH ki or WT mice. Also in vitro, XO ki mac-
rophages induced much higher Treg differentiation from naïve
T cells. Blocking ROS in vitro and in vivo resulted in reduced
Treg formation and reduced cancer growth, respectively. Taken
together, these findings provide the link between increased
macrophage ROS production, increased Tregs in tumors and
increased cancer growth in XO ki mice and were summarized
in Fig. 8.
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We also investigated whether uric acid, the product of XOR
activity, could mediate tumor growth in XO ki mice. It has been
reported that UA levels are higher in cancer patients56. Inter-
estingly, higher levels of uric acid in tumor-bearing rats were
associated with an increase in XO activity57. However, in our
study, we did not observe any significant differences in uric acid
levels between XDH ki, XO ki and WT mice, thus ruling out that
this metabolite is responsible for the tumor burden seen in XO
ki mice.
Our study also analyzed the Th1 and Th2 cytokine levels
in the supernatant of isolated macrophages after in vitro sti-
mulation. Pro-inflammatory Th1 cytokines (IL-12, IFN-γ)
have been found to play a major role in inhibiting and killing
tumor cells and impeding tumor growth. In contrast, Th2
cytokines have been proposed to facilitate tumor growth and
produce anti-inflammatory cytokines such as IL-1058–60.
Finally, different studies have demonstrated the ability of
TNFα to favor tumor escape from immune surveillance60,61. In
our study, IL-10 and TNFα cytokine levels were found to be
up-regulated in the supernatant of XO ki macrophages com-
pared to XDH ki cells. Increase of these cytokines in the tumor
microenvironment in XO ki mice may contribute to tumor
progression.
Here we show that XO ki and XDH ki macrophages differ-
entially influence the tumor microenvironment, thereby provid-
ing a new mechanism by which an imbalance within the
enzymatic XO/XDH ratio correlates with an increase of tumor
burden. Altogether our results suggest that a macrophage-specific
XO inhibitor that would reduce ROS levels but leave XDH
activity untouched may prove useful as a cancer therapeutic tool.
Methods
Animals. Xdh gene-modified mice were produced at Nippon Medical School. The
mouse knocked-in the XO form (W338A/F339L mutant), was named C57BL/6-
Xdhtm1/Nms. The mouse knocked-in the XDH-stable (C995R mutant) was named
C57BL/6-Xdhtm2/Nms. C57BL/6-Xdhtm1/Nms and C57BL/6-Xdhtm2/Nms were
abbreviated as XO ki and XDH ki, respectively. The details of the Xdh gene-
modified mice were described in the supplementary results. WT, XDH ki and XO
ki mice, all in the C57BL/6J background, were age and sex-matched in the different
experimental settings. WT mice were purchased from Harlan. Unless otherwise
stated, mice were used between 8–12 weeks old. All in vivo experimental protocols
were approved by the institutional animal care committees of the Nippon Medical
School and by the Swiss Federal and Cantonal Veterinary authorities, and
throughout the study, extreme care was taken to minimize animal pain and
discomfort.
Materials. ß-NAD+ (grade V-C), 4,4′-dithiodipyridine (4-DPS) and xanthine were
obtained from Sigma-Aldrich (St. Louis, MO). Dithiothreitol (DTT) was purchased
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All other chemicals and
reagents were of reagent grade, or equivalent, and were purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan) or Sigma-Aldrich Co. (St. Louis, MO).
Protein determination. Protein concentration was determined by the dye-binding
method of Bradford62 with bovine serum albumine as the standard. The con-
centration of bovine milk XOR and murine liver XOR was determined spectro-
photometrically using an extinction coefficient of 37.8 and 35.8 mM−1 cm−1 at
450 nm, respectively63,64.
XOR activity assay. Enzyme assays were carried out at 25 °C in 50mM potassium
phosphate buffer (pH 7.8) containing 0.4 mM EDTA and 0.15 mM xanthine for XO
activity. In the case of total activity (XO and XDH), 500 µM NAD+ was added to
the reaction. XOR activities (XO activity and total activity) were determined as urate
formation rate by monitoring the absorbance change at 295 nm. The extinction
coefficient of 9.6 mM−1 cm−1 for urate was used. Uric acid and O2− quantification
during xanthine-O2 turnover was described previously29. Photometric experiments
were performed with a UV-2550 spectrophotometer (Shimadzu, Kyoto, Japan). The
cell holder was water-jacketed and maintained at a constant temperature of 25.0 °C.
Electrophoresis. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on slab gels was performed by using a polyacrylamide gradient gel (Mini-
PROTEAN TGX 5–20%, Bio-Rad Laboratories Inc., Hercules, CA), according to
the method of Laemmli65. Mixture of recombinant proteins (Precision Plus Protein
Standards, Bio-Rad) was used as a molecular weight standard marker. Separated
proteins by SDS-PAGE were stained with fluorescent dye (Oriole fluorescent gel
stain, Bio-Rad) and were visualized by a gel imaging system (ChemiDoc XRS+,
Bio-Rad).
Western blotting analysis. Proteins resolved on a SDS-PAGE gel were blotted by
electrophoretic transfer into a PVDF membrane using the Trans-Blot Turbo
Blotting System (Bio-Rad). Western blots were washed with 0.05 M Tris-HCl (pH
7.6), 0.15M NaCl, 0.5% Tween 20 (TBS-T) for 5 min, and blocked for 1 h in 5% (w/
v) skimmed milk in TBS-T at ambient temperature. A rabbit polyclonal antibody
against rat XOR (laboratory-prepared antibody) and HRP conjugated goat poly-
clonal anti-rabbit antibody (1:2000, DAKO Cytomation, Glostrup, Denmark) was
used as a primary antibody and secondary antibody, respectively. The cross-react
signals were developed using the ECL Prime reagent (GE Healthcare UK Ltd.) and
were visualized by a gel imaging system (ChemiDoc XRS+, Bio-Rad).
Purification of XOR. Quality of the purified XOR enzymes were evaluated by using
activity flavin ratio (AFR)66. AFR was obtained by dividing the change in absor-
bance per min at 295 nm by the absorbance at 450 nm of the XOR enzyme used in
the assay. In the case of fully active XOR, AFR is around 200. The two mutants
XOR, XO ki (W338A/F339L), and XHD ki (C995R) were purified from mice liver
as described previously67; but using only the first affinity chromatography due to
limited amount of enzyme availability. Briefly, ammonium sulfate fraction from
liver soluble fraction was applied to an anion exchange column and a calcium





















Fig. 8 Proposed mechanisms of preferential tumor growth in XO ki mice. In vitro, XO ki macrophages generated more ROS and induce Treg differentiation
in a ROS dependent manner. In addition, they produce more inflammatory (IL-1, IL-6, and TNF) and anti-inflammatory (IL-10) cytokines. In vivo, XO ki
macrophages establish a tolerogenic microenvironment, increasing Treg accumulation in subcutaneously transferred tumors and thereby favor their
growth. A ROS scavenger (NAC) counteracts the pro-tumorigenic phenotype in XO ki mice, reestablishing tumor immunosurveillance (effects of NAC
indicated in red)
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according to the procedure of Nishino et al.68; but using only the first affinity
chromatography. The XDH and XO enzyme forms were treated with 5 mM DTT
or 0.1 mM 4-DPS for 1 h at 25 °C, respectively, and then passed through a sephadex
G-25 column (GE Healthcare Bio-Science Corp. Piscataway, NJ) to remove excess
DTT and 4-DPS. The D/O ratio as defined by Waud and Rajagopalan69 was
determined as the ratio of the absorbance change at 295 nm under aerobic con-
ditions in the presence of NAD to that in the absence of NAD. The bovine milk
XDH and the murine liver XDH samples used in this experiment had D/O ratio of
more than 7 and 5, respectively.
Preparation of bone-marrow-derived macrophages (BMDMs). 8–10-week-old
mice were euthanized and bone marrow cells were obtained from femurs by
flushing the bone marrow cavities with complete media (IMDM, 10% FCS, 0.5%
glutamax, 50 U/ml of penicillin, and 50 mg/ml streptomycin, and 20%
L929 supernatant (source of M-CSF)). Bone marrow cells were cultured for 3 days
in the complete medium in an incubator at 37 °C and 5% CO2. On the third and
fifth days, the medium was changed. After 7 days, the cells were detached and re-
plated at a density of 0.5 × 106 cells per 24-well culture dish. BMDMs cells were
treated overnight with 100 ng/ml LPS or with 100 ng/mL of Pam3CSK4 (Invitro-
gen). Culture supernatants were collected and total RNA or protein lysates were
prepared from the cells. All samples were stored at −80 °C until analysis. The
purity of the differentiated macrophages were verified by flow cytometry based on
their positive staining for F4/80 and CD11b.
Resident peritoneal exudate cells (PEC). Euthanized mice were injected i.p. with
3 mL of PBS, the abdomen was gently massaged for 60 s and then cells were
harvested, counted, and and resuspended in RPMI 1640 medium, supplemented
with 10% FCS.
Flow cytometric analysis. Cells were resuspended in fluorescence-activated cell
sorting (FACS) buffer (5% fetal calf serum plus 5 mM EDTA in PBS) and incu-
bated with conjugated monoclonal antibodies (mAb). The mAb used, phycoery-
thrin (PE)-conjugated anti–Ly-6G (clone RB6-8C5, 125931, 1/400), fluorescein
isothiocyanate (FITC)-conjugated anti-CD11b (clone M1/70, 11011241, and 1/
200), and allophycocyanin (APC)-conjugated anti-F4/80 (clone BM8, 17480182, 1/
800), eF450-conjugated anti-CD4 (clone RM4-5, 48004282, 1/200), PE-conjugated
anti–Foxp3 (clone FJK‐16 s, 12577382, 1/100), FITC-conjugated anti-CD25 (clone
PC61.5, 53025382, 1/400), APC-conjugated anti-Arginase-1 (clone A1exF5,
17369782, 1/100), APC-conjugated anti-EGR2 (clone erongr2, 17669182, 1/100),
were all from eBioscience. PE-conjugated anti-CD206 (clone CD68C2, 141705, 1/
100) and PE-conjugated anti-IL-6 (clone MP5-20F3, 504504, 1/100) were from
Biolegend. Cells (1 × 106) were incubated with appropriate conjugated antibodies
for 30 min at 4 °C in the dark. Stained cells were subsequently washed twice with
FACS buffer and fixed in BD CellFIX solution (BD Biosciences). Flow cytometric
analyses were performed on LSRII cytometer (Becton Dickinson) using FACS
Diva6 (Becton Dickinson) and FlowJoX (Tree Star) software for data processing.
ELISA. Supernatant samples were thawed and analyzed for secreted IL-10, IL-6,
and TNF-α by ELISA (eBioscience), according to the manufacturer’s protocol.
Plates were read at 450 nm in an ELISA reader (SpectraMAX 190 microplate
reader).
ROS measurement. Peritoneal exudate cells were cultured in 24-well plates (0.5 ×
106 cells per well) and incubated with LPS (100 ng/ml) or PMA (100 ng/ml). The
dye 2′, 7′-dichlorofluorescein diacetate (DCFH-DA, 10 μM) was added and incu-
bated in the dark at 37°C for 3 h. Cells were then washed twice with PBS and the
intensity of dichlorofluorescein (DCF) fluorescence in the cell was measured
by FACS.
Tumor experiments. CMT93 (ATCC, CCL-223) and MC38 (Kerafast, ENH204-
FP) colon carcinoma tumor cell lines and the B16 F0 melanoma cell line (ATCC,
CRL-6322) were cultured in DMEM medium supplemented with 10% FCS, and 50
U/ml of penicillin and 50 mg/ml streptomycin. Cell lines were tested negative for
mycoplasma. Tumors were induced by s.c. injection of 2 × 106 CMT93, MC38, or
B16 F0 cells into the flank of mice. In one experiment, XO ki or XDH ki BMDMs
(2 × 106 cells per mouse) were adoptively transferred by i.v. injection to WT mice
24 h after CMT93 tumor cell implantation. Tumor growth was followed by mea-
suring length and width using a caliper. Tumor volume was calculated using the
formula V= π 6⋅1.58⋅(length⋅width) as described by Wurzenberger et al.70.
Immunohistological analysis of tumors. At the end of the experiment, tumors
were dissected and paraffin embedded. Sections (5 μm) were stained with hema-
toxylin and eosin, and T cells, macrophage and endothelial cells staining performed
by immunohistochemistry using anti-CD3 (Abcam, ab16669, 1/100) anti-Mac-2
(Cedarlane, CL8942AP, 1/20) or anti-CD31 (Abcam, 28364, 1/200) antibodies,
respectively. Stainings were graded independently by two observers unaware of
mice genotype using a scoring system based on the severity of cell infiltration (for T
and macrophage cells) or the number of vessels counted per field (for endothelial
cells).
Bone marrow chimeras. Recipient male mice at 4 weeks of age were lethally
irradiated with 950 rads using an X-ray irradiator. Twenty-four hours post irra-
diation, bone marrow cells were obtained from femurs and tibia of donor mice
(WT, XDH ki and XO ki mice), and 107 bone marrow cells were injected i.v. into
irradiated recipient mice. Two month later, CMT93 tumor cells were injected s.c.
into the flank of mice. Tumor growth was followed by measuring the length and
width using a caliper as described above.
Gene expression analysis by real-time PCR. RNA was extracted from tumors or
BMDM. The qRT-PCR was performed using SYBR Green mix on LightCycler480
(384-well plate, 5 μL reaction) from Roche Diagnostics. The following primers
were used:
IL-10, F 5′-GCCTTATCGGAAATGATCCA-3′, R 5′-CTCCACTGCCTTGCT
C-3′; FPR2, F 5′-CACAGCAACTCTACCATTC-3′, R 5′-CAACCACCTTCCTAG
CCA-3′; EGR2, F 5′-ACACTACACCAGCAACTC-3′, R 5′-ACCACAACACATC
CACACA-3′; CCL2, F 5′-CATCCACTACCTTTTCCAC-3′, R 5′-GATCCACACC
TTGCATTT-3′; Arginase: F 5′-TGAGAGACCACGGGGACCTG-3′, R 5′-GCAC
CACACTGACTCTTCCATTC-3′; CD11b, F 5′-GAATGCTGCGAAGATCCTAG
TTGTC-3′, R 5′-CGGGACTGTGGTTTGTTGAAGG-3′; F4/80, F 5′-GCCTATT
ATCTATACCCTCCAGCACATC-3′, R 5′-TCCATCTCCCATCCTCCACATCA
G- 3; Granzyme B: 5′-AAGAACAGGAGAAGACCCA-3′ and 5′-AACCAGCCAC
ATAGCACA-3′; Hif1α: 5′-ACCTTCATCGGAAACTCCAAAG-3′ and 5′-CTGT
TAGGCTGGGAAAAGTTAGG-3′; G6PD: 5′-GGTAAAGGGGTGGTCTGATG
G-3′ and 5′-TGCGGGATACAAAGGGATGG-3′; IL-1β: 5′-CAACAAACAAGTG
ATATTCTCCATG-3′ and 5′-GTGCCGTCTTTCATTACACAG-3′; Casp-1: 5′-C
CGTGGAGAGAAACAAGGAG-3′ and 5′-ATGAAAAGTGAGCCCCTGAC-3′;
Hmox1 5′-GCCTCCAGAGTTTCCGCATA-3′ and 5′-AGGAAGCCATCACCAG
CTTA-3′; Hif2α: 5′-CAGCAAGGAGACGGA-3′ and 5′-GCAATGAACCCTCCA
AG-3′. The qRT-PCR was performed with technical triplicates. For the analysis,
expression of each gene was normalized to the house-keeping gene β-actin, F 5-G
CACAGCTTCTTTGCAGCTCCTTCG-3′, and R 5-TTTGCACATGCCGGAGCC
GTTG-3′. Relative change in mRNA expression was calculated using the qBasePlus
software (Biogazelle).
In vivo macrophage depletion. Liposome-encapsulated clodronate (dichlor-
omethylene bisphosphonate) or liposome-PBS were provided by LIPOSOMA,
Amsterdam, Netherlands, and were prepared according to the manufacturer’s
protocol. Mice were daily injected intraperitoneally with 200 μL of a clodronate-
loaded liposome suspension 4 times starting 3 days before tumor injection. Control
mice were injected with 200 μL PBS-loaded liposomes using the same schedule.
Determination of serum uric acid levels. Serum uric acid levels were measured
by using a quantitative enzymatic assay (Amplex Red kit, Invitrogen) according to
the manufacturer’s protocol. The results were standardized by using a commercial
uric acid standard solution.
In vitro differentiation of regulatory T cells. Total CD4+CD25− T cells from
spleen of OT-II mice were prepared using regulatory T cell isolation kit (Miltenyi
Biotec). Isolated CD4+CD25− T cells (105 cells/well) were co-cultured with their
corresponding XO ki or XDH ki BMDMs (2.104 cells/well) in 200 μl/well of
complete media plus 10 μM of OT-II peptide and 2 ng/ml TGFβ) at 37 °C for
5 days. Differentiation of regulatory T cells was determined by FACS using Foxp-3
staining kit (eBioscience).
N-Acetyl Cysteine (NAC) treatment. In vitro, NAC (Sigma) was added at 1 mM
to cell culture. In vivo, NAC was administered at 20 mM into the drinking water
for 24 h after tumor transfer until endpoint.
Graphical representation and statistical analysis. For in vitro experiments,
values represent mean ± SEM of triplicates from one representative experiment of
at least two independent experiments. For in vivo experiments, at least 5 mice per
group were used. Data were analyzed with GraphPad Prism 8.0 program. Variation
between data sets were evaluated using the Student’s t test or one-way Anova,
where appropriate. Difference were considered statistically significant at *p < 0.05,
**p < 0.01, ***p < 0.001.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are available from the authors. The
source data underlying all figures are provided in as a Source Data file (Supplementary
Data 1). A reporting summary for this article is available as a Supplementary Information
file.
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